title: Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.
abstract: The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development. The targeting of CD73 leads to reorganization of tumor microenvironment, shaping the phenotype of the infiltrating T cells. The development of CD73 monoclonal antibodies offers a promising new avenue for antineoplastic treatment.
authors.affiliation: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ, USA.
authors.forename: Luca
authors.initials: L
authors.lastname: Antonioli
authors.affiliation: Department of Clinical and Experimental Medicine, University of Pisa , Pisa, Italy.
authors.forename: Corrado
authors.initials: C
authors.lastname: Blandizzi
authors.affiliation: Laboratory of Immunogenetics and CeRMS, Department of Medical Sciences, University of Torino and Transplant Immunology, Città della Salute e della Scienza , Torino, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Malavasi
authors.affiliation: Department of Life Science and Biotechnology, University of Ferrara , Ferrara, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Ferrari
authors.affiliation: Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School , Newark, NJ, USA.
authors.forename: György
authors.initials: G
authors.lastname: Haskó
keywords: CD73; autophagy; immunotherapy; monoclonal antibody; tumor microenvironment